Edition:
United States

Becton Dickinson and Co (BDX.N)

BDX.N on New York Stock Exchange

179.81USD
26 Apr 2017
Change (% chg)

$0.74 (+0.41%)
Prev Close
$179.07
Open
$179.70
Day's High
$180.11
Day's Low
$178.34
Volume
474,693
Avg. Vol
251,703
52-wk High
$186.39
52-wk Low
$157.60

BDX.N

Chart for BDX.N

About

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of... (more)

Overall

Beta: 1.06
Market Cap(Mil.): $38,110.59
Shares Outstanding(Mil.): 212.83
Dividend: 0.73
Yield (%): 1.63

Financials

  BDX.N Industry Sector
P/E (TTM): 29.75 34.91 30.27
EPS (TTM): 6.02 -- --
ROI: 6.34 12.74 13.24
ROE: 17.67 14.80 14.40

BRIEF-BD licenses molecular indexing technology to Roche

* Becton Dickinson And Co - has non-exclusively licensed its patented stochastic labelling technology to Roche for multiple commercial applications

Apr 26 2017

Becton Dickinson to acquire Bard for $24 billion

NEW YORK U.S. medical equipment supplier Becton Dickinson and Co will acquire C R Bard Inc, in a $24 billion cash-and-stock deal, adding Bard's devices to its portfolio in the high-growth sectors of oncology and surgery, both companies said on Sunday. | Video

Apr 24 2017

BRIEF-Becton Dickinson, in connection with termination of merger, Bard must pay termination fee of $750 mln

* Becton Dickinson -in connection with termination of merger agreement under specified circumstances, Bard is required to pay co termination fee of $750 million Source text (http://bit.ly/2q6oN6S) Further company coverage:

Apr 24 2017

UPDATE 3-Becton Dickinson to acquire Bard for $24 billion

NEW YORK, April 23 U.S. medical equipment supplier Becton Dickinson and Co will acquire C R Bard Inc, in a $24 billion cash-and-stock deal, adding Bard's devices to its portfolio in the high-growth sectors of oncology and surgery, both companies said on Sunday.

Apr 23 2017

BRIEF-Becton Dickinson to buy Bard for $24 billion

* Deal immediately accretive and expected to generate high single-digit accretion to adjusted EPS in fiscal year 2019 to Becton Dickinson

Apr 23 2017

BD to acquire Bard in $24 bln medical tech deal

NEW YORK, April 23 Becton Dickinson and Co will acquire C R Bard Inc in a $24 billion deal that will give shareholders of the target about 15 percent of the combined entity, the two medical technology companies said on Sunday.

Apr 23 2017

BRIEF-BD receives FDA 510(k) clearance for new flow cytometer system

* BD receives FDA 510(k) clearance for new flow cytometer system with leucocount reagent assay Source text for Eikon: Further company coverage:

Apr 06 2017

BRIEF-Becton Dickinson announces early access program for BD Resolve single-cell analysis platform

* BD announces early access program for bd resolve single-cell analysis platform

Feb 13 2017

BRIEF-Retractable Technologies seeks review of decision in case against Becton Dickinson

* Retractable Technologies - On Jan 31, Co filed a petition for a writ of certiorari with Supreme Court of the United States

Feb 08 2017

BRIEF-Becton Dickinson Q1 earnings per share $2.58

* Becton dickinson and co says raising expected full fiscal year 2017 adjusted diluted earnings per share to $9.70 to $9.80

Feb 02 2017

More From Around the Web

Earnings vs. Estimates